{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:34:39Z","timestamp":1760243679894,"version":"build-2065373602"},"reference-count":93,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BeiGene, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Waldenstr\u00f6m macroglobulinemia (WM) is a slowly progressing B-cell non-Hodgkin lymphoma characterized by monoclonal IgM gammopathy in the blood and infiltration of the bone marrow by clonal lymphoplasmacytic cells. As an incurable disease, the goals for therapy for WM are to relieve symptoms, slow disease progression, prevent organ damage, and maintain quality of life. However, given the rarity of WM, clinical trials comparing treatments for WM are limited and there is no definitive standard of care. The selection of first-line WM therapy is thus based on patient factors, disease characteristics, and drug access, with bendamustine-rituximab and Bruton\u2019s tyrosine kinase (BTK) inhibitor therapy considered preferred treatments. Other treatments such as proteasome inhibitor- or purine analogue-based therapy, alternative chemoimmunotherapy, and autologous stem cell transplantation are generally reserved for the relapsed setting but may be used in rare circumstances in earlier lines of therapy. This paper summarizes the efficacy and safety of these WM therapies and discusses considerations for treatment from a Canadian perspective.<\/jats:p>","DOI":"10.3390\/curroncol29100560","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T20:58:47Z","timestamp":1664398727000},"page":"7122-7139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Canadian Perspective on the Treatment of Waldenstr\u00f6m Macroglobulinemia"],"prefix":"10.3390","volume":"29","author":[{"given":"Rayan","family":"Kaedbey","sequence":"first","affiliation":[{"name":"Department of Hematology, Jewish General Hospital, Montreal, QC H3T 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Forward","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dalhousie University\/Nova Scotia Health, Halifax, NS B3H 2Y9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, BC Cancer Centre for Lymphoid Cancer, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Shafey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Foothills Medical Centre and University of Calgary, Calgary, AB T2N 2T9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Doucette","sequence":"additional","affiliation":[{"name":"Impact Medicom Inc., Toronto, ON M6S 3K2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine I.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Suite 6-225, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: Evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"unstructured":"Leukemia & Lymphoma Society (2022, March 16). Waldenstr\u00f6m Macroglobulinemia Facts. Available online: https:\/\/www.lls.org\/sites\/default\/files\/file_assets\/waldenstrommacroglobulinemia.pdf.","key":"ref_2"},{"unstructured":"Waldenstrom\u2019s Macroglobulienmia Foundation of Canada (2022, March 16). Newly Diagnosed. Available online: https:\/\/www.wmfc.ca\/about-wm\/newly-diagnosed\/#:~:text=WM%20is%20a%20very%20rare%20cancer.,approximately%201500%20patients%20in%20total.","key":"ref_3"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1038\/s41375-019-0431-y","article-title":"A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis","year":"2019","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1182\/blood-2014-05-574871","article-title":"Survival trends in Waldenstr\u00f6m macroglobulinemia: An analysis of the Surveillance, Epidemiology and End Results database","volume":"123","author":"Castillo","year":"2014","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.13264","article-title":"Overall survival and competing risks of death in patients with Waldenstr\u00f6m macroglobulinaemia: An analysis of the Surveillance, Epidemiology and End Results database","volume":"169","author":"Castillo","year":"2015","journal-title":"Br. J. Haematol."},{"unstructured":"National Comprehensive Cancer Network (2022, March 15). Clinical Practice Guidelines in Oncology: Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma, Version 2.2022. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/waldenstroms.pdf.","key":"ref_8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/BLCTT.S259860","article-title":"Differential Diagnosis of Waldenstr\u00f6m\u2019s Macroglobulinemia and Early Management: Perspectives from Clinical Practice","volume":"12","author":"Cingam","year":"2022","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdy146","article-title":"Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Kastritis","year":"2018","journal-title":"Ann. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Leblond, V., Treon, S., and Dimoploulos, M. (2017). Waldenstr\u00f6m\u2019s Macroglobulinemia Immunophenotype. Waldenstr\u00f6m\u2019s Macroglobulinemia, Springer International Publishing.","key":"ref_11","DOI":"10.1007\/978-3-319-22584-5"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/blood-2012-06-436329","article-title":"MYD88 L265P mutation in Waldenstrom macroglobulinemia","volume":"121","author":"Poulain","year":"2013","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: Differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal architecture of CXCR4WHIM-like mutations in Waldenstr\u00f6m Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstr\u00f6m macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjh.15201","article-title":"Prevalence and survival of smouldering Waldenstr\u00f6m macroglobulinaemia in the United States","volume":"184","author":"Pophali","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1158\/1078-0432.CCR-04-1899","article-title":"Prognostic Validation of the International Classification of Immunoglobulin M Gammopathies: A Survival Advantage for Patients with Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance?","volume":"11","author":"Gobbi","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1182\/blood-2011-10-384768","article-title":"Progression in smoldering Waldenstr\u00f6m macroglobulinemia: Long-term results","volume":"119","author":"Kyle","year":"2012","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.19.00394","article-title":"Progression Risk Stratification of Asymptomatic Waldenstr\u00f6m Macroglobulinemia","volume":"37","author":"Bustoros","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood.V118.21.3692.3692","article-title":"Incidence of Peripheral Neuropathy in Waldenstr\u00f6m Macroglobulinemia Patients At Diagnosis","volume":"118","author":"Banwait","year":"2011","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3324\/haematol.2009.017251","article-title":"Pathophysiology of Waldenstrom\u2019s macroglobulinemia","volume":"95","author":"Stone","year":"2010","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","article-title":"Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.3109\/10428194.2015.1012714","article-title":"Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstr\u00f6m macroglobulinemia","volume":"56","author":"Tedeschi","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLML.2011.n.030","article-title":"Bendamustine therapy in patients with relapsed or refractory Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"11","author":"Treon","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstr\u00f6m macroglobulinemia: Final analysis of a phase 2 study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1200\/JCO.2007.10.9926","article-title":"Primary Treatment of Waldenstr\u00f6m Macroglobulinemia With Dexamethasone, Rituximab, and Cyclophosphamide","volume":"25","author":"Dimopoulos","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.15148","article-title":"Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr\u00f6m macroglobulinaemia","volume":"181","author":"Castillo","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstr\u00f6m macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2012.44.7920","article-title":"Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstr\u00f6m macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma","volume":"31","author":"Leblond","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2009.23.6315","article-title":"Rituximab and subcutaneous 2-chloro-2\u2019-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: Clinical and biologic results of a phase II multicenter study","volume":"28","author":"Laszlo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood-2008-09-177329","article-title":"Long-term outcomes to fludarabine and rituximab in Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Treon","year":"2009","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ajh.24405","article-title":"Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom\u2019s macroglobulinemia","volume":"91","author":"Souchet","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cncr.26303","article-title":"Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease","volume":"118","author":"Tedeschi","year":"2012","journal-title":"Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3816\/CLM.2009.n.016","article-title":"Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"9","author":"Ioakimidis","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1080\/10428190410001714043","article-title":"Multicenter Phase 2 Trial of Rituximab for Waldenstr\u00f6m Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)","volume":"45","author":"Gertz","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.critrevonc.2016.06.004","article-title":"Response rate to the treatment of Waldenstr\u00f6m macroglobulinemia: A meta-analysis of the results of clinical trials","volume":"105","author":"Garatachea","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.21.00838","article-title":"Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstr\u00f6m\u2019s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study","volume":"40","author":"Buske","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1200\/JCO.2002.09.039","article-title":"Treatment of Waldenstr\u00f6m\u2019s macroglobulinemia with rituximab","volume":"20","author":"Dimopoulos","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M flare after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia","volume":"101","author":"Ghobrial","year":"2004","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1097\/HS9.0000000000000603","article-title":"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma","volume":"5","author":"Gaitzsch","year":"2021","journal-title":"Hemasphere"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2006.07.8659","article-title":"Bortezomib Is Active in Patients With Untreated or Relapsed Waldenstr\u00f6m\u2019s Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1158\/1078-0432.CCR-06-2511","article-title":"Multicenter Clinical Trial of Bortezomib in Relapsed\/Refractory Waldenstrom\u2019s Macroglobulinemia: Results of WMCTG Trial 03-248","volume":"13","author":"Treon","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1200\/JCO.2009.25.3237","article-title":"Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenstr\u00f6m Macroglobulinemia","volume":"28","author":"Ghobrial","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1182\/blood.V114.22.3752.3752","article-title":"Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom\u2019s Macroglobulinemia","volume":"114","author":"Ghobrial","year":"2009","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-140933","article-title":"Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First-Line Treatment of Waldenstrom\u2019s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial","volume":"136","author":"Buske","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in newly diagnosed patients with WM: Final analysis of a phase 2 study after a minimum follow-up of 6 years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary Therapy of Waldenstr\u00f6m Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_52","first-page":"2772","article-title":"Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom\u2019s Macroglobulinemia","volume":"130","author":"Meid","year":"2017","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1182\/bloodadvances.2020001963","article-title":"Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstr\u00f6m macroglobulinemia: Long-term follow-up","volume":"4","author":"Castillo","year":"2020","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2019-122365","article-title":"Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom\u2019s Macroblobulinemia: Results of the Prospective Phase I\/II HOVON 124\/Ecwm-R2 Trial","volume":"134","author":"Kersten","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstr\u00f6m macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma Network (EMN)","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V128.22.618.618","article-title":"R2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for Initial Therapy of Waldenstr\u0151M\u2019s Macroglobulinemia: A Randomised Phase II Study","volume":"128","author":"Auer","year":"2016","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2018.78.6426","article-title":"Ibrutinib Monotherapy in Symptomatic, Treatment-Na\u00efve Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"36","author":"Treon","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41375-021-01417-9","article-title":"Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia","volume":"36","author":"Castillo","year":"2022","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-21-1497","article-title":"Single-Agent Ibrutinib for Rituximab-Refractory Waldenstr\u00f6m Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial","volume":"27","author":"Trotman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1200\/JCO.2022.40.16_suppl.7521","article-title":"ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenstr\u00f6m macroglobulinemia (WM)","volume":"40","author":"Tam","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: A single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/cas.14561","article-title":"A multicenter, open-label, phase II study of tirabrutinib (ONO\/GS-4059) in patients with Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"111","author":"Sekiguchi","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/bmt.2008.360","article-title":"High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom\u2019s macroglobulinemia","volume":"43","author":"Caravita","year":"2009","journal-title":"Bone Marrow Transpl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbmt.2007.01.083","article-title":"Autologous Stem Cell Transplantation as Part of First-Line Treatment of Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"13","author":"Dreger","year":"2007","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.V124.21.678.678","article-title":"Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom\u2019s Macroglobulinemia\/Lymphoplasmacytic Lymphoma (WM\/LPL). A Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party","volume":"124","author":"Kyriakou","year":"2014","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3324\/haematol.2009.017814","article-title":"Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom\u2019s macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"95","author":"Garnier","year":"2010","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/sj.bmt.1705748","article-title":"Evidence of graft-versus-Waldenstrom\u2019s macroglobulinaemia effect after allogeneic stem cell transplantation: A single centre experience","volume":"40","author":"Stakiw","year":"2007","journal-title":"Bone Marrow Transpl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clml.2022.02.005","article-title":"SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Sermer","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e004128","DOI":"10.1136\/jitc-2021-004128","article-title":"CD19-directed chimeric antigen receptor T cell therapy in Waldenstr\u00f6m macroglobulinemia: A preclinical model and initial clinical experience","volume":"10","author":"Palomba","year":"2022","journal-title":"J. Immunotherapy Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.HS9.0000843720.23634.a9","article-title":"S207: Efficacy and safety of a third generation CD20 CART (MB-106) for treatment of relapsed\/refractory follicular lymphoma (FL)","volume":"6","author":"Shadman","year":"2022","journal-title":"HemaSphere"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/hon.87_2881","article-title":"Phase I study of the CD19\/CD3 half-life extended BiTE\u00ae molecule AMG 562 in relapsed\/refractory diffuse large B cell lymphoma, mantle cell lymphoma and follicular lymphoma","volume":"39","author":"Mead","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2021-144350","article-title":"Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed\/Refractory Non-Hodgkin\u2019s Lymphoma","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed\/Refractory B-Cell Malignancies","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e20056","DOI":"10.1200\/JCO.2020.38.15_suppl.e20056","article-title":"Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenstr\u00f6m macroglobulinemia (WM)","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: A substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.15718","article-title":"Bendamustine plus rituximab in newly-diagnosed Waldenstr\u00f6m macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)","volume":"186","author":"Laribi","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"676792","DOI":"10.3389\/fonc.2021.676792","article-title":"Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Oncol."},{"doi-asserted-by":"crossref","unstructured":"Canadian Agency for Drugs and Technologies in Health (2022). CADTH Reimbursement Review-Zanubrutinib (Brukinsa). Can. J. Health Technol., 2, 1\u2013133.","key":"ref_89","DOI":"10.51731\/cjht.2022.453"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"760405","DOI":"10.3389\/fonc.2021.760405","article-title":"Preliminary Evaluation of Zanubrutinib-Containing Regimens in DLBCL and the Cerebrospinal Fluid Distribution of Zanubrutinib: A 13-Case Series","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/HS9.0000000000000155","article-title":"Efficacy of Zanubrutinib in the Treatment of Bing-Neel Syndrome","volume":"2","author":"Wong","year":"2018","journal-title":"Hemasphere"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.2147\/OTT.S309408","article-title":"Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib","volume":"14","author":"Cheng","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"672052","DOI":"10.3389\/fonc.2021.672052","article-title":"Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/560\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:26Z","timestamp":1760143286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/10\/560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":93,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["curroncol29100560"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29100560","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}